SCOPUS 정보 검색 플랫폼

Volumn 47, Issue 9, 2007, Pages 1138-1151

Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a Protein kinase C-β inhibitor, in healthy subjects

(6) Welch, Pamela A a Sinha, Vikram P a Cleverly, Ann L a Darstein, Christelle a Flanagan, Shawn D a Musib, Luna C a

a ELI LILLY AND COMPANY (United States)

Author keywords

Enzastaurin; Pharmacokinetics; Phase I; Protein kinase C

Indexed keywords

DRUG METABOLITE; ENZASTAURIN; LY 326020; LY 485912; PLACEBO; PROTEIN KINASE C BETA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEADACHE; HOLTER MONITORING; HUMAN; MALE; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; QT INTERVAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HEADACHE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SLEEP;

EID: 58349117702 PISSN: 00912700 EISSN: 15524604 Source Type: Journal
DOI: 10.1177/0091270007304775 Document Type: Article

Times cited : (20)

References (18)

1
- 0038394537
- Acyclic N-(azacycloalkyl)bisindolylmaleimides: Isozyme selective inhibitors of PKCß
- Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCß. BioorgMed Chem Lett. 2003;13:1857-1859.
- (2003) BioorgMed Chem Lett. , vol.13 , pp. 1857-1859
- Faul, M.M.¹ Gillig, J.R.² Jirousek, M.R.³

2
- 23844521568
- The protein kinase Cß-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma grafts
- Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cß-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma grafts. Cancer Res. 2005;65:7462-7469.
- (2005) Cancer Res. , vol.65 , pp. 7462-7469
- Graff, J.R.¹ McNulty, A.M.² Hanna, K.R.³

3
- 0032213794
- Analogs of staurosporine: Potential anticancer drugs?
- DOI 10.1016/S0306-3623(98)00069-X, PII S030636239800069X
- Gescher A. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol. 1998;31:721-728. (Pubitemid 28520048)
- (1998) General Pharmacology , vol.31 , Issue.5 , pp. 721-728
- Gescher, A.¹

4
- 0035657643
- Protein kinase C inhibitors as novel anticancer drugs
- DOI 10.1517/13543784.10.12.2117
- Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs. 2001;10:2117-2140. (Pubitemid 34000377)
- (2001) Expert Opinion on Investigational Drugs , vol.10 , Issue.12 , pp. 2117-2140
- Goekjian, P.G.¹ Jirousek, M.R.²

5
- 0033386539
- Protein kinase C targeting in antineoplastic treatment strategies
- DOI 10.1023/A:1006328303451
- Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs. 1999;17:227-240. (Pubitemid 30037956)
- (1999) Investigational New Drugs , vol.17 , Issue.3 , pp. 227-240
- Jarvis, W.D.¹ Grant, S.²

6
- 0023764824
- The molecular heterogeneity of protein kinase C and its implications for cellular regulation
- DOI 10.1038/334661a0
- Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988;334:661-665. (Pubitemid 18197563)
- (1988) Nature , vol.334 , Issue.6184 , pp. 661-665
- Nishizuka, Y.¹

7
- 0032987224
- Inhibition of protein kinase C - Do we, can we, and should we?
- DOI 10.1016/S0163-7258(98)00047-3, PII S0163725898000473
- Parker PJ. Inhibition of protein kinase C: do we, can we, and should we? Pharmacol Ther. 1999;82:263-267. (Pubitemid 29255921)
- (1999) Pharmacology and Therapeutics , vol.82 , Issue.2-3 , pp. 263-267
- Parker, P.J.¹

8
- 0033105841
- Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells
- KingLB,NorvellA,MonroeJG.Antigenreceptor- inducedsignaltransductionimbalancesassociated withthenegativeselectionofimmatureBcells.JImmunol.1999;162:2655-2662. (Pubitemid29309286)
- (1999) Journal of Immunology , vol.162 , Issue.5 , pp. 2655-2662
- King, L.B.¹ Norvell, A.² Monroe, J.G.³

9
- 18244409933
- Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
- DOI 10.1038/nm0102-68
- Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74. (Pubitemid 34101731)
- (2002) Nature Medicine , vol.8 , Issue.1 , pp. 68-74
- Shipp, M.A.¹ Ross, K.N.² Tamayo, P.³ Weng, A.P.⁴ Kutok, J.L.⁵ Aguiar, R.C.T.⁶ Gaasenbeek, M.⁷ Angelo, M.⁸ Reich, M.⁹ Pinkus, G.S.¹⁰ Ray, T.S.¹¹ Koval, M.A.¹² Last, K.W.¹³ Norton, A.¹⁴ Lister, T.A.¹⁵ Mesirov, J.¹⁶ Neuberg, D.S.¹⁷ Lander, E.S.¹⁸ Aster, J.C.¹⁹ Golub, T.R.²⁰ more..

10
- 0033199874
- Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
- YoshijiH,KuriyamaS,WaysDK,etal. ProteinkinaseCliesonthesignalingpathway forvascularendothelialgrowthfactormediatedtumordevelopmentandangiogenesis. CancerRes.1999;59:4413-4418.(Pubitemid29418762)
- (1999) Cancer Research , vol.59 , Issue.17 , pp. 4413-4418
- Yoshiji, H.¹ Kuriyama, S.² Ways, D.K.³ Yoshii, J.⁴ Miyamoto, Y.⁵ Kawata, M.⁶ Ikenaka, Y.⁷ Tsujinoue, H.⁸ Nakatani, T.⁹ Shibuya, M.¹⁰ Fukui, H.¹¹

11
- 0442329299
- LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
- DOI 10.1007/s00280-003-0713-x
- Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53:133-140. (Pubitemid 38186992)
- (2004) Cancer Chemotherapy and Pharmacology , vol.53 , Issue.2 , pp. 133-140
- Keyes, K.A.¹ Mann, L.² Sherman, M.³ Galbreath, E.⁴ Schirtzinger, L.⁵ Ballard, D.⁶ Chen, Y.-F.⁷ Iversen, P.⁸ Teicher, B.A.⁹

12
- 33746627036
- ICH E14 Rockville, MD: US Department of Health and Human Services, FDA; October www .fda.gov/cber/gdlns/ichel4qtc.pdf. Accessed December 18 2006
- ICH E14. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for NonAntiarrhythmic Drugs. Rockville, MD: US Department of Health and Human Services, FDA; October 2005. Available at: www .fda.gov/cber/gdlns/ichel4qtc.pdf. Accessed December 18, 2006.
- (2005) Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for NonAntiarrhythmic Drugs

13
- 0033634992
- Confidence interval criteria for assessment of dose proportionality
- Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278-1283.
- (2000) Pharm Res. , vol.17 , pp. 1278-1283
- Smith, B.P.¹ Vandenhende, F.R.² Desante, K.A.³

14
- 0004061014
- 2nd ed. New York: Marcel Dekker
- Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
- (1982) Pharmacokinetics
- Gibaldi, M.¹ Perrier, D.²

15
- 0035023187
- Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
- SwaislandH,LaightA,StaffordL,etal. Pharmacokineticsandtolerabilityoftheorally activeselectiveepidermalgrowthfactor receptortyrosinekinaseinhibitorZD1839inhealthyvolunteers.ClinPharmacokinet. 2001;40:297-306.(Pubitemid32458155)
- (2001) Clinical Pharmacokinetics , vol.40 , Issue.4 , pp. 297-306
- Swaisland, H.¹ Laight, A.² Stafford, L.³ Jones, H.⁴ Morris, C.⁵ Dane, A.⁶ Yates, R.⁷

16
- 4644287353
- Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
- DOI 10.1007/s00280-004-0832-z
- Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 2004;54:290-294. (Pubitemid 39304422)
- (2004) Cancer Chemotherapy and Pharmacology , vol.54 , Issue.4 , pp. 290-294
- Dutreix, C.¹ Peng, B.² Mehring, G.³ Hayes, M.⁴ Capdeville, R.⁵ Pokorny, R.⁶ Seiberling, M.⁷

17
- 33748670455
- Phase i dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
- DOI 10.1200/JCO.2005.05.3447
- Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24:4092-4099. (Pubitemid 46622284)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.25 , pp. 4092-4099
- Carducci, M.A.¹ Musib, L.² Kies, M.S.³ Pili, R.⁴ Truong, M.⁵ Brahmer, J.R.⁶ Cole, P.⁷ Sullivan, R.⁸ Riddle, J.⁹ Schmidt, J.¹⁰ Enas, N.¹¹ Sinha, V.¹² Thornton, D.E.¹³ Herbst, R.S.¹⁴

18
- 0030428256
- Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans
- Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996;24:475-490.
- (1996) J Pharmacokinet Biopharm. , vol.24 , pp. 475-490
- Wilkinson, G.R.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.